Su, B., Yao, C., Zhao, Q., Cai, W., Wang, M., Lu, H., Mu, T., Chen, Y., Liu, L., Wang, H., He, Y., Zheng, Y., Li, L., Chen, J., Yu, J., Zhu, B., Zhao, M., Sun, Y., Lun, W., Zhang, Y., Wang, H., Xia, W., Sun, L., Dai, L., Jiang, T., Wang, M., Zheng, Q., Peng, H., Wang, Y., Hu, M., Liu, X., Lu, R., Hu, J., Sun, C., Xing, H., Shao, Y., Xie, D., Zhang, T., Zhang, F., & Wu, H. (2022). long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. Journal of infection, 85(3), 334–363. http://access.bl.uk/ark:/81055/vdc_100160124961.0x000050